You are using an outdated browser. Please upgrade your browser to improve your experience.

trelagliptin

Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus.
Target Activities